Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
, Schokker E
, Jacob L
Full Text Sources
The goal was to analyze differences between the baseline characteristics of type 2 diabetes mellitus (T2DM) patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors in three randomized clinical trials (RCTs) and those receiving the same treatment in a German real-world setting.
PMID: 30049306 [PubMed - as supplied by publisher]